Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Stemirac’s 44 Million Yen Sales Within Expectations, Says Nipro President
November 15, 2019
- Big 3 Generic Firms Enjoy 7.8% Growth, AG Makers Triumph: Jiho Tally
November 15, 2019
- Fujifilm to Make 13 Billion Yen Investment in Gene Therapy Facilities in US
November 15, 2019
- Big 4 Japan Wholesalers Eke Out 1% Operating Margins: Jiho Tally
November 14, 2019
- Kyowa Pharma Set to Accelerate Beyond-the-Pill Growth after Lupin’s Divestment Deal: Chief
November 14, 2019
- Otsuka/Avanir to Carry On Development of Alzheimer’s Agitation Drug
November 14, 2019
- Otsuka’s Pharma Biz Zooms 14.0% in January-September on 4 Global Brands
November 14, 2019
- Ajinomoto, Kanagawa Cancer Center Team Up for Research for Next-Gen Treatment/Diagnosis Technology
November 14, 2019
- Rohto to Snap Up Nitten Pharmaceutical to Tap Into Ethical Eye Drop Arena
November 14, 2019
- Half of R&D Money Going towards Cancer Meds, Exec Says Oncology Will Be GSK’s “Next Respiratory”
November 13, 2019
- AstraZeneca, Omron Healthcare Pair Up to Develop Disease Management Solutions
November 13, 2019
- Ono, BMS File Opdivo/Yervoy Combo for MSI-H Colorectal Cancer in Japan
November 13, 2019
- Sandoz to Buy Aspen’s Japan Biz for Up to 400 Million Euros
November 12, 2019
- Mitsubishi Tanabe’s HIF-PH Inhibitor Shows Non-Inferiority to ESA in Japan PIII Study
November 12, 2019
- Japan Ethical Drug Sales Spike 19.7% in September: Crecon
November 12, 2019
- Satralizumab Submitted in Japan for NMOSD
November 11, 2019
- Esaxerenone Hits Primary Goal in Japan PIII Study for Diabetic Nephropathy: Daiichi Sankyo
November 11, 2019
- Ninlaro Meets Primary Endpoint as 1st-Line Maintenance Therapy for Multiple Myeloma: Takeda
November 11, 2019
- Nippon Kayaku Forecasts 4.3 Billion Yen Full-Year Sales for Biosimilars
November 11, 2019
- BI Japan and Nippon BI to Merge in January Next Year to Increase Management Efficiency
November 11, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…